Topical delivery of paclitaxel for treatment of skin cancer

References

• Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B Biol 2001;63:8–18.
   PubMed Web of Science ®Google Scholar
• Arthur JS, Darragh J. Signaling downstream of p38 in psoriasis. J Invest Dermatol 2006;126:1689–91.
   PubMed Web of Science ®Google Scholar
• Chouinard N, Valerie K, Rouabhia M, Huot J. UVB mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53. Biochem J 2002;365:133–45.
   PubMed Web of Science ®Google Scholar
• Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 2003;23:6836–48.
   PubMed Web of Science ®Google Scholar
• Hildesheim J, Awwad RT, Fornace AJ Jr. p38 Mitogen activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J Invest Dermatol 2004;122:497–502.
   PubMed Web of Science ®Google Scholar
• Barrera MV, Herrera E. Topical chemotherapy of actinic keratosis and nonmelanoma skin cancer: current options and future perspectives. Actas Dermo-Sifiliográficas 2007;98:556–62.
   PubMedGoogle Scholar
• Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191–202.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590–8.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Rowinsky EK, Rosenhein NB. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989;111:273–9.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147–55.
   PubMed Web of Science ®Google Scholar
• Wong K-K. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4:28–35.
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794–847.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65.
   PubMed Web of Science ®Google Scholar
• Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992;52:3776–81.
   PubMed Web of Science ®Google Scholar
• He L, Wang GL, Zhang Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int J Pharm 2003;250:45–50.
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003;22:7280–95.
   PubMed Web of Science ®Google Scholar
• Meerum Terwogt JM, Nuijen B, Ten Bokkel Huinink WW, Beijnen JH. Alternative formulations of paclitaxel. Cancer Treat Rev 1997;23:87–95.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 2000;50:61–77.
   PubMed Web of Science ®Google Scholar
• Chen D-B, Yang T-Z, LU W-L, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001;49:1444–7.
   PubMed Web of Science ®Google Scholar
• Souto EB, Doktorovova S. Chapter 6 – solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Meth Enzymol 2009;464:105–29.
   PubMed Web of Science ®Google Scholar
• Prow T, Smith JN, Grebe R, et al. Construction, gene delivery, and expression of DNA tethered nanoparticles. Mol Vis 2006;12:606–15.
   PubMed Web of Science ®Google Scholar
• Murthy RS. Solid lipid nanoparticles as carriers for anti-cancer drugs to solid tumours. Drug Deliv 2005;12:385–92.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006;6:2991–5.
   PubMed Web of Science ®Google Scholar
• Zhao QH, Zhang Y, Liu Y, et al. Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med Oncol 2010;27:203–12.
   PubMed Web of Science ®Google Scholar
• Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011;63:470–91.
   PubMed Web of Science ®Google Scholar
• Baroli B, Ennas MG, Loffredo F, et al. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol 2007;127:1701–12.
   PubMed Web of Science ®Google Scholar
• Üner M, Karaman EF. Preliminary studies on solid lipid microparticles of loratadine for the treatment of allergic reactions via the nasal route. Trop J Pharm Res 2013;12:287–93.
   Web of Science ®Google Scholar
• Wissing SA, Muller RH. A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosmet Sci 2001;23:233–43.
   PubMedGoogle Scholar
• Annette Zur M, Core S, Wolfgang M. Formulation and Evaluation of solid lipid nanoparticles containing anti-inflammatory drugs. Eur J Pharm Biopharm 1998;45:149–55.
   PubMed Web of Science ®Google Scholar
• Seikmann B, Westesen K. Investigation on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm 1996;43:104–9.
   Google Scholar
• Eldem T, Speiser P, Hincal A. Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991;8:47–54.
   PubMed Web of Science ®Google Scholar
• Cavalli R. The effect of the components of microemulsion on both size and crystalline structure of solid lipid nanoparticles containing a number of model molecules. Pharmazie 1998;53:392–6.
   Web of Science ®Google Scholar
• Ahlin P, Kristl J, Kobar S. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersion. Acta Pharm 1998;48:257–67.
   Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006;58:1688–713.
   PubMed Web of Science ®Google Scholar
• Meyer E, Heinzelmann H. Scanning force microscopy. In: Wiesendanger R, Guntherodt HJ, eds. Scanning tunneling microscopy II, surface science. New York: Springer Verlag; 1992:99–149.
   Google Scholar
• Nasr M, Mansour S, Mortada ND. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2008;9:123–31.
   Web of Science ®Google Scholar
• Slavomira D, Garcia ML. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B Biointerfaces 2010;75:538–42.
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71–7.
   PubMed Web of Science ®Google Scholar
• Jain SK, Chourasia MK, Masuriha R, et al. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 2005;12:207–15.
   PubMed Web of Science ®Google Scholar
• Shah M, Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech 2010;11:489–96.
   PubMed Web of Science ®Google Scholar
• Kyo YC, chung JF. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloids Surf B Biointerfaces B 2011;83:299–306.
   PubMed Web of Science ®Google Scholar
• Ekambaram P, Abdul HSA. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216–20.
   PubMedGoogle Scholar
• Bhasker K, Anbu J. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 2009;8:6–15.
   PubMed Web of Science ®Google Scholar
• Sanjay J, Padsalg A, Patel K, Moale V. Formulation development and evaluation of fluconazole gel in various polymer base. Asian J Pharm 2007;1:63–8.
   Google Scholar
• Martinez MAR, Gallardo JLV, Benavides MMD, et al. Rheological behavior of gels and meloxicam release. Int J Pharm 2007;333:17–23.
   PubMed Web of Science ®Google Scholar
• Kumar TG, Kaur LP. Formulation and evaluation of topical gel of aceclofenac. J Drug Deliv Ther 2013;3:51–3.
   Google Scholar
• Kaur LP, Garg R, Gupta GD. Development and evaluation of topical gel of minoxidil from different polymer bases in application of alopecia. Int J Pharm Sci 2010;2:43–7.
   Google Scholar
• de Vringer T. Topical preparation containing a suspension of solid lipid particle. European Patent No. 91200664; 1992.
   Google Scholar
• Edwards DA, Langer R. A linear theory of transdermal transport phenomena. J Pharm Sci 1994;83:1315–34.
   PubMed Web of Science ®Google Scholar
• Yumune MA, Williams AC, Barry BW. Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. J Pharm Pharmacol 1995;47:978–89.
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharm Res 1991;8:17–24.
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JMS. Evaluation of mathematical model describing drug release from estradiol transdermal systems. DDIP 2003;27:89–97.
   Google Scholar
• Sachan NK, Bhattacharya A. Modeling and characterization of drug release from glutinous rice starch based hydrogel beads for control drug delivery. Int J Health Res 2009;2:93–9.
   Google Scholar
• Wilna L, Eileen EA. Comparative study of the release of active ingredients from semisolid cosmeceuticals measured with Franz, enhancer or flow-through cell diffusion apparatus. J Food Drug Anal 2004;12:19–28.
   Web of Science ®Google Scholar
• Prakash PR, Rao NR, Chowdary S. Formulation, evaluation and anti-inflammatory activity of topical etoricoxib gel. Asian J Pharm Clinical Res 2010;3:126–9.
   Google Scholar
• Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 1992;17:77–83.
   PubMed Web of Science ®Google Scholar
• Ofer N, Moshe A, Ora M, et al. Anti-neoplastic activity of paclitaxelon experimental superficial bladder cancer: in-vivo and in-vitro studies. Int J Cancer 1997;70:297–301.
   PubMed Web of Science ®Google Scholar
• Paolino D, Celia C, Trapasso E, et al. Paclitaxel-loaded ethosomes potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm 2012;81:102–12.
   PubMed Web of Science ®Google Scholar
• Hosmer JM, Steiner AA, Lopes LB. Lamellar liquid crystalline phases for cutaneous delivery of paclitaxel: impact of the monoglyceride. Pharm Res 2013;30:694–706.
   PubMed Web of Science ®Google Scholar
• Kilfoyle BE, Sheihet L, Zhang Z, et al. Development of paclitaxel-tyrospheres for topical skin treatment. J Control Release 2012;163:18–24.
   PubMed Web of Science ®Google Scholar
• Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol 2007;127:154–62.
   PubMed Web of Science ®Google Scholar
• Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 2008;363:132–8.
   PubMed Web of Science ®Google Scholar
• Shenoy VS, Vijay IK, Murthy RSR. Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 2005;57:411–22.
   PubMed Web of Science ®Google Scholar
• Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170–84.
   PubMed Web of Science ®Google Scholar
• Severino P, Fangueiro JF, Ferreira SV, et al. Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials. Clin Transl Oncol 2013;15:417–24.
   PubMed Web of Science ®Google Scholar
• Swant KK, Petkar CK, Agrawal Y. Development, evaluation and clinical studies of acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm 2010;401:93–102.
   PubMed Web of Science ®Google Scholar
• Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003;24:1781–5.
   PubMed Web of Science ®Google Scholar
• Rohan S, Daniel E, Enzo P, Ian H. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci 2014;25:59–75.
   Google Scholar
• Averineni RK, Shavi GV, Gurram AK, et al. PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mater Sci 2012;35:319–26.
   Web of Science ®Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech 2011;12:712–22.
   PubMed Web of Science ®Google Scholar
• Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU J Pharm Sci 2015;23:46.
   Web of Science ®Google Scholar
• Luo YF, Chen DW, Ren LX, et al. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 2006;114:53–9.
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Savic S, Vuleta G, et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm 2011;406:163–72.
   PubMed Web of Science ®Google Scholar
• Fei H, Sanming L, Ran Y, et al. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2008;315:210–16.
   Web of Science ®Google Scholar
• Barratt G. Characterization of the colloidal drug carrier systems with zeta potential measurements. Pharm Tech Eur 1999;11:25–32.
   Google Scholar
• Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech 2012;13:125–33.
   PubMed Web of Science ®Google Scholar
• Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289–300.
   PubMed Web of Science ®Google Scholar
• Gokce EH, Korkmaz E, Dellera E, et al. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012;7:1841–50.
   PubMed Web of Science ®Google Scholar
• Westesen K, Bunjes H, Koch MJH. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997;48:223–36.
   Web of Science ®Google Scholar
• Qi C, Chen Y, Jing Q-Z, Wang X-G. Preparation and characterization of catalase-loaded solid lipid nanoparticles protecting enzyme against proteolysis. Int J Mol Sci 2011;12:4282–93.
   PubMed Web of Science ®Google Scholar
• Schubert MA, Harms M, Muller RH, Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci 2006;27:226–36.
   PubMed Web of Science ®Google Scholar
• Casadei MA, Cerreto F, Cesa S, et al. Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations. Int J Pharm 2006;325:140–6.
   PubMed Web of Science ®Google Scholar
• Hu QF, Jiang S, Du YZ, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005;45:167–73.
   PubMed Web of Science ®Google Scholar
• Ceve G. Lipid vesicles and other colloidal as drug carriers on the skin. Adv Drug Del Rev 2004;56:675–711.
   PubMed Web of Science ®Google Scholar
• Degim T, Hadgraft J, Pugh WJ. Modelling the transdermal delivery of non-steroidal anti-inflammatory agents. Proc Int Symp Control Release Bioactive Mater 1995;22:652–3.
   Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72.
   PubMed Web of Science ®Google Scholar
• Feng L, Russell JM. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 2013;334:157–75.
   PubMed Web of Science ®Google Scholar